Pages that link to "Q44606433"
Jump to navigation
Jump to search
The following pages link to Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning (Q44606433):
Displaying 50 items.
- Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose (Q30558271) (← links)
- Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect (Q33381924) (← links)
- A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti‐tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice (Q33829731) (← links)
- Prolonged Survival of Subcutaneous Allogeneic Islet Graft by Donor Chimerism without Immunosuppressive Treatment. (Q33872942) (← links)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio (Q34202277) (← links)
- Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. (Q35093521) (← links)
- Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission (Q35181654) (← links)
- Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. (Q35828638) (← links)
- A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells. (Q36062047) (← links)
- The hope and the reality of reduced intensity transplants in children with malignant diseases (Q36090213) (← links)
- High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (Q36117735) (← links)
- The graft-versus-lymphoma effect: clinical review and future opportunities (Q36128232) (← links)
- Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Q36310235) (← links)
- Quo vadis haemapheresis. Current developments in haemapheresis (Q36368041) (← links)
- Induction of tumor immunity following allogeneic stem cell transplantation (Q36490755) (← links)
- Improved strategy for mononuclear cell collection for donor lymphocyte infusions (Q36492568) (← links)
- Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning (Q36548358) (← links)
- Optimization of allogeneic transplant conditioning: not the time for dogma (Q36556498) (← links)
- Novel approaches in allogeneic stem cell transplantation (Q36562204) (← links)
- Graft-versus-leukemia in chronic lymphocytic leukemia (Q36745408) (← links)
- Graft-versus-host disease after donor leukocyte infusions: presentation and management (Q36825001) (← links)
- Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. (Q36863475) (← links)
- Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant (Q36977560) (← links)
- Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation (Q37008223) (← links)
- Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. (Q37176587) (← links)
- What is the role for donor natural killer cells after nonmyeloablative conditioning? (Q37327327) (← links)
- Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation (Q37445265) (← links)
- Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. (Q37492611) (← links)
- Adoptive T-cell therapy for B-cell malignancies (Q37810116) (← links)
- Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia (Q37829878) (← links)
- Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks (Q37849773) (← links)
- Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I). (Q38029953) (← links)
- Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation (Q38105635) (← links)
- Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer (Q38198742) (← links)
- Reduced-intensity conditioned allogeneic SCT in adults with AML. (Q38366632) (← links)
- New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. (Q38643400) (← links)
- Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation (Q38660984) (← links)
- Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. (Q40966061) (← links)
- The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia (Q42151172) (← links)
- Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. (Q45162502) (← links)
- Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005. (Q46319967) (← links)
- High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation (Q46384949) (← links)
- Severe intestinal graft versus host disease after donor lymphocyte infusion; response to extracorporeal photochemotherapy (Q46693351) (← links)
- Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. (Q47592938) (← links)
- Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial (Q50069823) (← links)
- Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. (Q54534706) (← links)
- Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma (Q57209660) (← links)
- Donor T-cell responses and disease progression patterns of multiple myeloma (Q57560891) (← links)
- Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST (Q59620668) (← links)
- A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation (Q80493822) (← links)